Dendreon: The Opportunity for Investors

Although Dendreon's (NASDAQ: DNDN  ) performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as Provenge became a lightning rod of debate. But where does that leave investors? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 10, 2013, at 11:47 PM, lebronz wrote:

    Now ur learning David.

    Treating 1076 patients per quarter is the magic number for dndn (= $100M in rev).

    Even at 1076 patients or 4304 per year, that is still barely making a dent in the 30,000 that are "newly diagnosed" with mCRPC throughout a year.

    And we're not even including the 60k men "living" with mCRPC (men newly diagnosed with mCRPC typically have 2 years to live).

    Cheers!

    Leb

Add your comment.

DocumentId: 2189941, ~/Articles/ArticleHandler.aspx, 7/24/2014 7:04:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement